Responses
Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
79 Tumor-immune signatures associated with response or resistance to tislelizumab (Anti-PD-1) in esophageal squamous cell carcinoma (ESCC)
Compose a Response to This Article
Other responses
No responses have been published for this article.